Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

30-07-2018 | Osteoporosis | Review | Article

Glucocorticoid-Induced Osteoporosis: Update on Management

Journal: Current Treatment Options in Rheumatology

Authors: Aprajita Jagpal, MD, Kenneth G. Saag, MD

Publisher: Springer International Publishing

Login to get access

Abstract

Purpose of review

Glucocorticoids (GCs) are potent anti-inflammatory and immunosuppressant drugs that are used to treat many inflammatory conditions across different fields of medicine. Glucocorticoid-induced osteoporosis (GIOP) is a significant comorbidity associated with long-term steroid use (> 3 months). The purpose of this review is to provide an update in the management of glucocorticoid-induced osteoporosis.

Recent findings

New data for use of denosumab in GIOP includes a large clinical trial showing greater gains in bone density and no differences in adverse effects compared to risedronate. Another study suggests a reduction in hip fractures with alendronate. Meta-analyses and systematic reviews demonstrate an increase in bone mineral density as well as reduction in vertebral fractures with bisphosphonates in GIOP. Recent guidelines from the American college of Rheumatology provide concise suggestions for screening, prevention, and treatment of patients with GIOP. Adequate clinical fracture risk assessment should be obtained for each patient who is expected to receive glucocorticoids for long term. All patients should receive calcium, vitamin D supplementation, and lifestyle counselling. Pharmacologic treatment should be offered to patients who have a moderate to high risk of fractures. Oral followed by IV bisphosphonate remain the first line of treatment. The guidelines recommend other agents including teriparatide and denosumab to be considered as second- and third-line agents, respectively.

Summary

Glucocorticoid-induced osteoporosis caused by long-term steroid use is associated with significant comorbidity and is often under-treated by clinicians. New clinical trials, meta-analyses, and guidelines offer new strategies for assessment and management.
Literature
1.
Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011;50(11):1982–90.CrossRef
2.
Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294–8.CrossRef
3.
Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2003;15(4):454–7.CrossRefPubMed
4.
Van Staa TP, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.CrossRefPubMed
5.
Van Staa TP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–9.CrossRefPubMed
6.
Balasubramanian A, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239–49.CrossRefPubMed
7.
Majumdar SR, et al. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int. 2013;24(9):2493–8.CrossRefPubMed
8.
Angeli A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–9.CrossRefPubMed
9.
• Amiche MA, et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018;13(1):30. A population-based case-control study shows substantial increase in hip fracture risk with high glucocortiocid doses.CrossRefPubMedPubMedCentral
10.
van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87.CrossRefPubMed
11.
Majumdar SR, et al. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J Clin Endocrinol Metab. 2012;97(4):1236–42.CrossRefPubMed
12.
Thanou A, et al. Utilization of Preventive Measures for Glucocorticoid-Induced Osteoporosis among Veterans with Inflammatory Bowel Disease. ISRN Gastroenterol. 2013;2013:862312.PubMedPubMedCentralCrossRef
13.
van Staa TP, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005;98(3):191–8.CrossRefPubMed
14.
Francesco L, et al. Assessing Risk of Osteoporotic Fractures in Primary Care: Development and Validation of the FRA-HS Algorithm. Calcif Tissue Int. 2017;100(6):537–49.CrossRefPubMed
15.
Kanis JA, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–16.CrossRefPubMed
16.
•• Buckley, L., et al., 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken), 2017. 2017 American College of Rheumatology guidelines provide updated strategies for prevention and management of GIOP.
17.
•• Amiche MA, et al. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. J Bone Miner Res. 2018;33(3):419–29. A study using health care administrative claims data shows reduced vertebral fracture risk with all oral bisphosphonates and reduced hip fracture risk with alendronate and risedronate among patients on chronic GC treatment.CrossRefPubMed
18.
Thomas T, et al. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Osteoporos Int. 2013;24(1):263–9.CrossRefPubMed
19.
• Axelsson KF, et al. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. JAMA. 2017;318(2):146–55. A retrospective obervational study shows reduced hip fracture risk with alendronate among older patients on glucocorticoids.CrossRefPubMedPubMedCentral
20.
• Shin K, et al. Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial. Clin Ther. 2017;39(2):268–278.e2. A randomized controlled trial showing benefit of ibandronate in reducing bone mineral loss in Korean women with rheumatoid arthritis on glucocorticoid treatment.CrossRefPubMed
21.
Saag KG, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55.CrossRefPubMed
22.
Glüer CC, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–68.CrossRefPubMedPubMedCentral
23.
• Saag KG, et al. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. Arthritis Rheumatol. 2016;68(9):2122–8. This study shows that teriparatide increases trabecular bone score in patients with GIOP.CrossRefPubMed
24.
Cummings SR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefPubMed
25.
Sawamura M, et al. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids. Intern Med. 2017;56(6):631–6.CrossRefPubMedPubMedCentral
26.
Ishiguro S, et al. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos. 2017;12(1):44.CrossRefPubMed
27.
Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–8.CrossRefPubMed
28.
Suzuki, T., Y. Nakamura, and H. Kato, Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol, 2018: p. 1-5.
29.
•• Saag, K.G., et al., Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol, 2018. A randomized controlled double blind trial shows that denosumab is non inferior and superior to risedronate for effect on bone mineral density in lumbar spine in patients on GC therapy, without significant increase in adverse effects.
30.
Overman RA, et al. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015;26(5):1515–24.CrossRefPubMedPubMedCentral
31.
• Kan SL, et al. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis. Medicine (Baltimore). 2016;95(25):e3990. A metanalysis of of randomized controlled trials of alendronate for prevention of GIOP in rheumatic diseases suggests that alendronate increases bone mineral density at lumbar spine, total hip and trochanter.CrossRef
32.
Feng Z, et al. Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis. PLoS One. 2013;8(12):e80890.CrossRefPubMedPubMedCentral
33.
• Allen CS, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:CD001347. A cochrane review of 27 randomized controlled trials of bisphosphonates for the prevention and treatment of GIOP in adults on glucocorticoids, shows evidence that biosphosphonates are beneficial in reducing vertebral fractures.PubMed
34.
• Liu CL, et al. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med. 2017;40(3):E146–57. A meta-analysis shows that teriparatide increases bone mineral density of lumbar spine, total hip and femoral neck in patients with GIOP.CrossRefPubMed
35.
Grossman JM, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26.CrossRef
36.
Maricic, M., et al., Comment on 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken), 2017.
37.
Yu SF, et al. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey. Medicine (Baltimore). 2017;96(5):e5959.CrossRefPubMedCentral
38.
• Trijau S, et al. Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD Open. 2016;2(2):e000249. This study highlights the inadequacies in the management of GIOP.CrossRefPubMedPubMedCentral
Image Credits